Helix BioPharma Corp. saw a notable increase in its stock price, reflecting positive investor sentiment.
Helix BioPharma Corp. (HBP.TO) experienced a significant uptick in its stock price, rising by 10.68% in yesterday's trading session. This increase comes amid ongoing developments in the biotech sector, which often influences investor confidence.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$87.07M
52W high
$5.40
52W low
$0.96
1W change
-21.38%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 119.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+119.3% Upside
Current Price
C$1.14
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
101.9%
Annualized
90-Day Vol
70.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.07 | C$0.76 – C$1.53 |
| 60 trading days | C$1.01 | C$0.62 – C$1.66 |
| 90 trading days | C$0.95 | C$0.52 – C$1.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors may view Helix BioPharma's recent stock performance as a sign of potential recovery or growth, despite the company reporting a net loss in its latest financial results.
Stock Price Climbs to CA$1.14
With a market cap of about CA$87 million, Helix BioPharma's stock price increase reflects growing interest in the biotech sector, even with its ongoing financial challenges.
Bull case
The rise in Helix BioPharma's stock could show renewed investor interest, likely fueled by optimism about future clinical developments or strategic initiatives that might improve the company's market position.
Bear case
However, investors should stay cautious. The company has reported significant net losses, which could raise concerns about its financial health and long-term sustainability.
Stock Performance Overview
Advertisement
Helix BioPharma Corp.'s stock price closed at CA$1.14, marking a notable increase of 10.68% from the previous session. This performance stands out in a market where biotech stocks can be highly volatile, suggesting a possible shift in investor sentiment.
Financial Context
Despite the positive stock movement, Helix BioPharma recently reported a net loss of CA$5.2 million for the fiscal year. Investors should consider this financial backdrop against the recent surge, as it highlights the ongoing challenges the company faces.
Looking Ahead
As Helix BioPharma continues to navigate its financial hurdles, investors will be closely watching for any announcements about clinical developments or strategic partnerships that could further influence stock performance. For more detailed insights on Helix BioPharma, visit the Wealth Awesome stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
